Alnylam Pharmaceuticals (NASDAQ:ALNY) Insider Melissa Mclaughlin Sells 1,624 Shares

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) insider Melissa Mclaughlin sold 1,624 shares of the firm’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $319.59, for a total transaction of $519,014.16. Following the transaction, the insider directly owned 11,729 shares of the company’s stock, valued at $3,748,471.11. The trade was a 12.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Melissa Mclaughlin also recently made the following trade(s):

• On Monday, April 6th, Melissa Mclaughlin sold 2,286 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $330.42, for a total transaction of $755,340.12.

Alnylam Pharmaceuticals Trading Down 3.3%

Shares of ALNY stock traded down $10.82 during trading hours on Tuesday, hitting $319.52. 1,305,095 shares of the company’s stock traded hands, compared to its average volume of 1,372,175. The stock’s 50 day simple moving average is $326.15 and its 200 day simple moving average is $393.92. The stock has a market cap of $42.37 billion, a PE ratio of 186.85 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $495.55. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The business had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.16 billion. During the same period in the previous year, the business posted ($0.65) EPS. Alnylam Pharmaceuticals’s revenue was up 84.9% on a year-over-year basis. On average, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Root Financial Partners LLC acquired a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at about $25,000. MV Capital Management Inc. bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $25,000. Salomon & Ludwin LLC bought a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at about $27,000. HM Payson & Co. bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $27,000. Finally, Golden State Wealth Management LLC lifted its position in shares of Alnylam Pharmaceuticals by 100.0% during the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 36 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have commented on ALNY. Truist Financial reduced their price target on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating for the company in a report on Thursday, January 8th. Oppenheimer began coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 price target for the company. Royal Bank Of Canada reduced their price target on shares of Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating for the company in a report on Tuesday, January 20th. Morgan Stanley reduced their price target on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a report on Friday, January 30th. Finally, Bank of America restated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $473.87.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.